These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39163191)

  • 1. Discovery of Pyrazolo[1,5-
    Wang C; Zou F; Qi Z; Liu Q; Shen L; Yuan X; Deng M; Wang A; Wang B; Wang L; Liang X; Liu Q; Liu J
    J Med Chem; 2024 Sep; 67(17):15199-15219. PubMed ID: 39163191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
    Jia H; Dai G; Su W; Xiao K; Weng J; Zhang Z; Wang Q; Yuan T; Shi F; Zhang Z; Chen W; Sai Y; Wang J; Li X; Cai Y; Yu J; Ren P; Venable J; Rao T; Edwards JP; Bembenek SD
    J Med Chem; 2019 May; 62(10):4936-4948. PubMed ID: 31033293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia.
    Tang Y; Zheng Y; Hu X; Zhao H; Cui S
    J Med Chem; 2024 Apr; 67(8):6638-6657. PubMed ID: 38577724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
    Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor.
    Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Moritomo A; Kubo S; Nakamura K; Yamagami K; Hamakawa N; Yokoo K; Fukahori H
    Bioorg Med Chem; 2018 Aug; 26(14):3917-3924. PubMed ID: 29907471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and biological evaluation of novel pyrazolopyridine derivatives as potent and orally available PI3Kδ inhibitors.
    Hamajima T; Takahashi F; Kato K; Mukoyoshi K; Yoshihara K; Yamaki S; Sugano Y; Moritomo A; Yamagami K; Yokoo K; Fukahori H
    Bioorg Med Chem; 2018 May; 26(9):2410-2419. PubMed ID: 29631787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of (
    Li F; Liang X; Jiang Z; Wang A; Wang J; Chen C; Wang W; Zou F; Qi Z; Liu Q; Hu Z; Cao J; Wu H; Wang B; Wang L; Liu J; Liu Q
    J Med Chem; 2020 Nov; 63(22):13973-13993. PubMed ID: 33180507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.
    Feng Y; Duan W; Fan S; Zhang H; Zhang SQ; Xin M
    Bioorg Med Chem; 2019 Oct; 27(19):115035. PubMed ID: 31434616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
    Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
    Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.
    Piddock RE; Loughran N; Marlein CR; Robinson SD; Edwards DR; Yu S; Pillinger GE; Zhou Z; Zaitseva L; Auger MJ; Rushworth SA; Bowles KM
    Blood Cancer J; 2017 Mar; 7(3):e539. PubMed ID: 28282033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Optimization of Pyridazinones as PI3Kδ Selective Inhibitors for Administration by Inhalation.
    Bruno P; Micoli A; Corsi M; Pala D; Guariento S; Fiorelli C; Ronchi P; Fioni A; Gallo PM; Marenghi G; Bertolini S; Capacchi S; Mileo V; Biagetti M; Capelli AM
    J Med Chem; 2024 Jul; 67(13):11103-11124. PubMed ID: 38907711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-
    Yu Y; Han Y; Zhang F; Gao Z; Zhu T; Dong S; Ma M
    J Med Chem; 2020 Mar; 63(6):3028-3046. PubMed ID: 32069401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Potent and Selective PI3Kγ Inhibitors.
    Drew SL; Thomas-Tran R; Beatty JW; Fournier J; Lawson KV; Miles DH; Mata G; Sharif EU; Yan X; Mailyan AK; Ginn E; Chen J; Wong K; Soni D; Dhanota P; Chen PY; Shaqfeh SG; Meleza C; Pham AT; Chen A; Zhao X; Banuelos J; Jin L; Schindler U; Walters MJ; Young SW; Walker NP; Leleti MR; Powers JP; Jeffrey JL
    J Med Chem; 2020 Oct; 63(19):11235-11257. PubMed ID: 32865410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
    Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing Small Molecule PI3Kγ Inhibitors: A Review of Structure-Based Methods and Computational Approaches.
    Yin X; Wang J; Ge M; Feng X; Zhang G
    J Med Chem; 2024 Jul; 67(13):10530-10547. PubMed ID: 38988222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
    Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
    Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
    Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
    Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis.
    Yu M; Wang X; Tang Y; Wang L; Hu X; Weng Q; Wang J; Cui S
    J Med Chem; 2024 Jun; 67(11):9628-9644. PubMed ID: 38754045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues.
    Yevale D; Teraiya N; Lalwani T; Dalasaniya M; Kapadiya K; Ameta RK; Sangani CB; Duan YT
    Bioorg Chem; 2024 Jun; 147():107323. PubMed ID: 38583254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.